Direkt zum Inhalt
Merck

04273

Sigma-Aldrich

Natriumphosphat dibasisch Dodecahydrat

meets analytical specification of Ph. Eur., BP, E339, 98.5-102.5% (T)

Synonym(e):

sec-Natriumphosphat, Dinatrium-hydrogenphosphat Dodecahydrat, Dinatriumphosphat, di-Natriumhydrogenphosphat Dodecahydrat

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise


About This Item

Lineare Formel:
Na2HPO4 · 12H2O
CAS-Nummer:
Molekulargewicht:
358.14
EG-Nummer:
MDL-Nummer:
UNSPSC-Code:
12161700
PubChem Substanz-ID:
NACRES:
NA.25

Agentur

meets analytical specifications of BP
meets analytical specifications of Ph. Eur.

Qualitätsniveau

Assay

98.5-102.5% (T)

Form

crystals

Qualität

meets analytical specification of Ph. Eur., BP, E339

Verunreinigungen

reducing matter, complies
residual solvents, complies
≤0.001% heavy metals (as Pb)
≤1.0% NaH2PO4
57-61% water (Karl Fischer)

Verlust

57-61% loss on drying

pH-Wert

8.4-9.6 (20 °C, 1%)

Anionenspuren

chloride (Cl-): ≤10 mg/kg
fluoride (F-): ≤10 mg/kg
sulfate (SO42-): ≤100 mg/kg

Kationenspuren

As: ≤1 mg/kg
Cd: ≤1 mg/kg
Cu: ≤20 mg/kg
Fe: ≤10 mg/kg
Hg: ≤1 mg/kg
K: ≤50 mg/kg
Pb: ≤4 mg/kg
Zn: ≤10 mg/kg

Eignung

complies for appearance of solution

SMILES String

O.O.O.O.O.O.O.O.O.O.O.O.[Na+].[Na+].OP([O-])([O-])=O

InChI

1S/2Na.H3O4P.12H2O/c;;1-5(2,3)4;;;;;;;;;;;;/h;;(H3,1,2,3,4);12*1H2/q2*+1;;;;;;;;;;;;;/p-2

InChIKey

DGLRDKLJZLEJCY-UHFFFAOYSA-L

Suchen Sie nach ähnlichen Produkten? Aufrufen Leitfaden zum Produktvergleich

Anwendung


  • Study of the Influence of Alkalizing Components on Matrix Pellets Prepared by Extrusion/Spheronization: This publication examines the effects of sodium phosphate dibasic dodecahydrate as an alkalizing agent in matrix pellets, showcasing its application in improving the physicochemical properties of pellets, which are crucial for controlled drug delivery systems (Hamedelniel EI, Bajdik J, Kasa P Jr, Pintye-Hodi K, 2012).

Lagerklassenschlüssel

11 - Combustible Solids

WGK

WGK 1

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable


Analysenzertifikate (COA)

Suchen Sie nach Analysenzertifikate (COA), indem Sie die Lot-/Chargennummer des Produkts eingeben. Lot- und Chargennummern sind auf dem Produktetikett hinter den Wörtern ‘Lot’ oder ‘Batch’ (Lot oder Charge) zu finden.

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Kunden haben sich ebenfalls angesehen

Yuichiro Yano et al.
Journal of the American College of Cardiology, 65(4), 327-335 (2015-01-31)
Isolated systolic hypertension (ISH), defined as systolic blood pressure (SBP) ≥140 mm Hg and diastolic blood pressure (DBP) <90 mm Hg, in younger and middle-aged adults is increasing in prevalence. The aim of this study was to assess the risk
Karen Sliwa et al.
Heart (British Cardiac Society), 100(24), 1967-1974 (2014-09-18)
Lack of evidence-based data on the spectrum of cardiovascular disease (CVD) in pregnancy or in the postpartum period, as well as on maternal and fetal outcome, provides challenges for treating physicians, particularly in areas of low resources. The objectives of
Luciano Candilio et al.
Heart (British Cardiac Society), 101(3), 185-192 (2014-09-26)
Remote ischaemic preconditioning (RIPC), using brief cycles of limb ischaemia/reperfusion, is a non-invasive, low-cost intervention that may reduce perioperative myocardial injury (PMI) in patients undergoing cardiac surgery. We investigated whether RIPC can also improve short-term clinical outcomes. One hundred and
George G S Sandor et al.
International journal of cardiology, 179, 470-475 (2014-12-04)
Patients with Marfan (MFS) and Loeys-Dietz (LDS) syndromes have been shown to have abnormal aortic biophysical properties. The purpose of this study was to compare the effects of 12-months of therapy with atenolol or losartan on vascular function in young
Matthew R Weir et al.
Journal of clinical hypertension (Greenwich, Conn.), 16(12), 875-882 (2014-10-21)
The effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure (BP) and osmotic diuresis- and intravascular volume reduction-related adverse events (AEs) were evaluated using pooled data from four placebo-controlled, phase 3 studies in patients with type 2

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.